Loading clinical trials...

Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy | Clinical Trials | Clareo Health

RECRUITINGPHASE4

Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy

Effects of Minocycline on Patients With Acute Anterior Circulation Ischemic Stroke Undergoing Intravenous Thrombectomy

NCT05487417•Xijing Hospital

View on ClinicalTrials.gov

Summary

Minocycline is the second generation of tetracycline. Because of its lipophilicity, it has high penetrance of blood-brain barrier. Animal model studies have shown that minocycline can reduce cerebral damage after ischemic stroke, and its mechanism involves multiple molecular pathways, such as antioxidant, anti-inflammatory, anti apoptotic pathways, and protection of blood-brain barrier. Clinical studies have also shown that minocycline can significantly improve 3-month National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) of patients with ischemic stroke, indicating that minocycline is a potential neuroprotective drug. Minocycline is believed to protect the blood-brain barrier, thereby reducing the ischemia-reperfusion injury caused by mechanical thrombectomy. However, whether minocycline can become a synergistic treatment method of mechanical thrombectomy, there is no clinical research in this area at present. Therefore, investigators carry out the study on the effect of minocycline in patients with acute anterior circulation ischemic stroke after mechanical thrombectomy, and plan to enroll 180 patients. To explore the safety and effectiveness of minocycline in patients with acute ischemic stroke after thrombectomy.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients with acute cerebral infarction of anterior circulation accompanied by large vessel occlusion;
•2. Age 18-85 years old;
•3. The time of onset ≤ 6 hours or ≤ 24 hours suitable for mechanical thrombectomy determined by multimodal imaging;
•4. The time of onset 6-24 hours, DWI shows an infarct volume less than 1/3 of the MCA blood supply area; the time of onset ≤ 6 hours, the ASPECTS(Alberta Stroke Program Early CT Score) is ≥6;
•5. Preoperative NIHSS score ranges from 6 to 30 points;
•6. Sign the informed consent form;

Exclusion Criteria

•1. There are contraindications for mechanical thrombectomy;
•2. No revascularization therapy was performed during the operation or the TICI score after revascularization therapy was less than 2b;
•3. There are other major central nervous system diseases, such as brain injury, brain tumor, multiple sclerosis, etc;
•4. There is evidence that the patient has bacterial endocarditis, aortic dissection, arteritis or venous cerebral infarction;
•5. Renal insufficiency or hepatic insufficiency (serum creatinine \>2.0 mg/dL or 180 µmol/L; liver function greater than 3 times the normal value);
•6. Known history of congestive heart failure (requiring dietary or medication changes or hospitalization) within 6 months, or myocardial infarction within 6 months;
•7. There is evidence of any other life-threatening or severe diseases that may hinder the completion of the 3-month follow-up and affect the evaluation of the results;
•8. Pre-existing neurological deficits or history of dementia;
•9. There are infectious diseases that require antibiotic treatment before the disease;
•10. Allergic to tetracyclines or unable to take minocycline for other reasons;
+4 more criteria

Locations (1)

Xijing Hospital

Xi'an, China

Key Dates

Start Date

November 1, 2022

Primary Completion Date

June 10, 2025

Completion Date

September 10, 2025

Last Updated

July 24, 2025

Enrollment

180

ESTIMATED participants

Conditions

Ischemic Stroke, Acute

Interventions

Minocycline

DRUG

Contacts

Wen Jiang, Ph.D

CONTACT

86-029-84771319 jiangwen@fmmu.edu.cn

Fang Yang, Ph.D

CONTACT

86-029-84771319 fyangx@fmmu.edu.cn

Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry

NCT06075628

Atrial FibrillationIschemic Stroke, Acute

View study

RECRUITINGNA

Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition

NCT06094478

Stroke, AcuteIschemic Stroke, Acute+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy

Inclusion Criteria

Exclusion Criteria

Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry

Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition

Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-B )

Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）

Dysphagia After Transesophageal Echocardiography in Acute Stroke - Follow Up Trial